Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis (Q24245033)

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab for treatment of steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Outcome of a conservative approach in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Is infliximab effective for induction of remission in patients with ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab as a novel therapy for pediatric ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Use of infliximab in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Use of infliximab in the treatment of Crohn's disease in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Accuracy of data in abstracts of published research articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Empirical assessment of effect of publication bias on meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Infliximab for patients with refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

[Infliximab as treatment for a severe outbreak of ulcerative colitis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Infliximab for refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

The incidence and management of infusion reactions to infliximab: a large center experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005112.PUB2

7 January 2021

10.1002/14651858.CD005112.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16856078

1 reference

Consolidated OpenCitations Corpus – April 2017